Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

140.55 -0.68 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
41 42 Next >
Expert Ratings For Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) with... 
Via Benzinga
Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free
Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ... 
Via Benzinga
Is Warren Buffett Making A Mistake By Selling These Stocks?
Warren Buffett is a hero of mine. However, Buffett is human like the rest of us, and he makes mistakes. Well, he might be making a mistake right now. 
Via Talk Markets
Biogen: What to Do When Your Investment Thesis Is Disproven
It's bound to happen eventually, so it's best to have a contingency plan. 
Via The Motley Fool
Cassava Stock Dives Again As Lab Distances Itself From 'Data Manipulation' Allegations
The lab that tested samples for Cassava's Alzheimer's study distanced itself from the biotech Friday, and SAVA stock plunged again. 
Via Investor's Business Daily
Expert Ratings For Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst r... 
Via Benzinga
Analyst Ratings for Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the... 
Via Benzinga
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
The second-quarter earnings season was a strong one for the drug/biotech sector. 
Via Talk Markets
Warren Buffett Sold Off This Biotech Stock. Should You?
A recent regulatory approval could make this company worth serious consideration. 
Via The Motley Fool
White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people... 
Via Benzinga
Exposures Product Safety
Could Biogen Acquire Axsome Therapeutics?
Here are three reasons why a buyout just might happen. 
Via The Motley Fool
Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's
Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300... 
Via Benzinga
Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and... 
Via Benzinga
Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2
Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (... 
Via Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What... 
Via Benzinga
Exposures COVID-19
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
Is There Any Hope Left for This Alzheimer's Drug Developer?
Biogen is reeling from charges that its drug doesn't work. 
Via The Motley Fool
How Much Should An Alzheimer's Drug Cost?
The answer is more complicated than you think. 
Via The Motley Fool
Cassava Sciences vs. Biogen
Who will emerge victorious in the race to help Alzheimer's patients? 
Via The Motley Fool
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:... 
Via Benzinga
What to Do After Cassava Sciences Dropped Off a Cliff
Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. 
Via InvestorPlace
Why I Sold My Biogen Stock
It has everything to do with Aduhelm. 
Via The Motley Fool
Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?
Probably. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Is Now a Good Time to Buy Biogen Stock?
It's a definite maybe. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Why Biogen's Stock Has Likely Peaked
The stock has a tough road back to $400, assuming it can get back there at all. 
Via The Motley Fool
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases... 
Via Benzinga
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday. 
Via Investor's Business Daily
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.